Arterial hypertension developing 10 years after radiotherapy for Wilms's tumour.
نویسندگان
چکیده
منابع مشابه
Arterial hypertension developing 10 years after radiotherapy for Wilms's tumour.
Three patients developed arterial hypertension more than 10 years after receiving irradiation for Wilm's tumour. Scattered radiation appeared to have caused changes in the remaining kidney which were not severe enough to inhibit compensatory hypertrophy but which produced a rise in blood pressure at a later date. Since arterial hypertension appears to be a delayed complication of radiotherapy w...
متن کاملKlatskin's tumour 10 years after successful cadaveric renal transplantation.
Successful outcome of renal transplantation depends on prevention of graft rejection with lmmunosuppressive drugs. These drugs also have numerous undesirable side-effects, which include an increased incidence of neoplasm particularly skin cancer and lymphoma. Visceral neoplasia occurring de novo, however, is less commonly seen following renal transplantation [1-3]. Storms and Ramli first descri...
متن کاملDeveloping treatments for pulmonary arterial hypertension
Developing new treatments for pulmonary arterial hypertension (PAH) is a challenge. We have enjoyed success with regulatory approvals for three drug classes-prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors. But we have also seen some disappointing results, for example, from studies with vasoactive intestinal polypeptide, statins and tergolide. Animal models a...
متن کاملProgression of Carotid Arterial Stiffness With Treatment of Hypertension Over 10 Years
Hypertension affects ≈80 million adults in the United States, and its prevalence is increasing as the population ages. Elevated systolic blood pressure (BP) is associated with progression of carotid arterial stiffening. Treating hypertension reduces cardiovascular disease (CVD) and stroke events, an observation that may be mediated, in part, by slowing progressive arterial stiffening. Previous ...
متن کاملPegvisomant: Balance after 10 years.
El pegvisomant (PEG) fue aprobado por la Agencia Europea del Medicamento en noviembre del 2002 para pacientes con acromegalia persistente tras la cirugía y no controlados con análogos de la somatostatina (SSA). En España se comercializó en el año 2004, por lo que transcurridos más de 10 años parece adecuado reflexionar sobre nuestra experiencia con su uso, revisar los últimos datos sobre su efi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1982
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.285.6347.996